NCT03829371View on ClinicalTrials.gov

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

PHASE4RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

January 3, 2019

Primary Completion Date

January 3, 2027

Study Completion Date

January 3, 2030

Conditions
Multiple Myeloma
Interventions
DRUG

Velcade

Subcutaneous use

DRUG

Melphalan

Oral use

DRUG

Prednisone

Oral use

DRUG

Lenalidomide

Oral use

DRUG

Dexamethasone

Oral use

DRUG

Daratumumab

Subcutaneous Injection

Trial Locations (1)

10126

RECRUITING

Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Torino

All Listed Sponsors
lead

University of Turin, Italy

OTHER